- Home
- KYIV vs NAMS Comparison
KYIV vs NAMS Comparison
Compare KYIV & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$25.20
Company Overview
Basic Information| Metric | KYIV | NAMS |
|---|---|---|
| Founded | 1994 | 2019 |
| Country | United Arab Emirates | Netherlands |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.1B |
| IPO Year | 2025 | 2022 |
Fundamental Metrics
Financial Performance| Metric | KYIV | NAMS |
|---|---|---|
| Price | $13.40 | $25.20 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 8 |
| Target Price | $16.85 | ★ $46.75 |
| AVG Volume (30 Days) | 274.0K | ★ 1.1M |
| Earning Date | 05-13-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.81 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $22,503,000.00 |
| Revenue This Year | $10.63 | $17.96 |
| Revenue Next Year | $7.11 | $540.65 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.29 | $23.05 |
| 52 Week High | $16.55 | $42.21 |
Technical Indicators
Market Signals| Indicator | KYIV | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 47.43 | 32.45 |
| Support Level | $13.05 | N/A |
| Resistance Level | $13.42 | $28.87 |
| Average True Range (ATR) | 0.30 | 1.04 |
| MACD | 0.08 | -0.03 |
| Stochastic Oscillator | 53.53 | 9.34 |
Price Performance
Historical Comparison KYIV
NAMS
About KYIV Kyivstar Group Ltd.
Kyivstar Group Ltd is engaged in mobile communication.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.